Lekoklar (Clarithromycin)

• Clarithromycin is a macrolide antibiotic that targets bacterial infections of the respiratory and gastrointestinal tracts.
• Community‑acquired pneumonia: effective in eradicating the causative bacteria and improving clinical outcomes.
• Acute bacterial sinusitis: reduces infection severity and accelerates symptom resolution.
• Helicobacter pylori eradication (in combination therapy): contributes to bacterial clearance as part of triple‑therapy regimens.

• Clarithromycin binds to the 50S subunit of bacterial ribosomes, inhibiting the translocation step of protein synthesis. By blocking the movement of peptidyl‑tRNA from the A site to the P site, it prevents elongation of the polypeptide chain, leading to bacteriostatic activity against susceptible Gram‑positive and some Gram‑negative organisms. The drug accumulates intracellularly, achieving concentrations that exceed the minimum inhibitory concentrations for target pathogens, and its high tissue penetration enhances efficacy in respiratory and soft‑tissue sites.

Clarithromycin may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects

• Nausea: mild stomach upset.
• Diarrhea: loose stools.
• Taste disturbance: altered taste perception.

Serious or Rare Side Effects

• Severe allergic reactions (anaphylaxis): potentially life‑threatening hypersensitivity.
• QT interval prolongation: risk of cardiac arrhythmia.
• Hepatotoxicity: liver enzyme elevation or injury.

• Before prescribing Lekoklar, clinicians should consider several safety measures.
• Assess renal and hepatic function before initiating therapy.
• Avoid use in patients with known macrolide hypersensitivity.
• Monitor cardiac status in patients with arrhythmia risk.
• Consider drug‑drug interaction potential, especially with CYP3A4 substrates.
• Use with caution in pregnancy and breastfeeding due to limited data.
• Store at ambient temperature (below 25°C): keep in original packaging, protect from moisture.

Clarithromycin interacts with several medicines; awareness of interaction severity guides clinical decisions.

Major Interactions (Avoid)

• Concurrent use with strong CYP3A4 inhibitors (e.g., ketoconazole) may cause toxicity.
• Co‑administration with drugs that prolong QT interval (e.g., cisapride) increases risk of arrhythmia.
• Combination with colchicine can lead to severe toxicity.

Moderate Interactions (Monitor Closely)

• CYP3A4 inducers (e.g., rifampin) may reduce clarithromycin levels.
• Warfarin may have increased anticoagulant effect.
• Statins metabolized by CYP3A4 (e.g., simvastatin) may have increased risk of myopathy.